Live news related to GENFIT stock (FR0004163111): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on GENFIT mainly cover earnings publications, M&A activity et analyst notes. The stock trades at €13,44 on Euronext Paris, up 0,75% at the last update. This page lists the articles published on GENFIT stock to track the share price, company announcements and any item likely to influence market perception.
Genfit announced on July 2nd the acquisition of Medicare coverage for NASHnext, its non-invasive diagnostic test for metabolic steatohepatitis (MASH).…
GENFIT announced positive Phase 1b data for GNS561 in combination with a MEK inhibitor in patients with KRAS-mutated cholangiocarcinoma, previously tr…
Genfit announced on Monday the launch of NASHnext, a non-invasive diagnostic service based on its NIS4 technology, through Labcorp's OnDemand platform…
Genfit announced on Monday the availability of its NASHnext diagnostic test on the digital platform Labcorp OnDemand, allowing patients to access scre…
Genfit announced on Monday a strong scientific presence at the EASL 2026 congress, with seven accepted posters covering its main assets in acute decom…
Genfit generated €9.6 million in revenue during the first three months of 2026 from royalties on Ipsen's sales of Iqirvo. This outcome arrived earlier…
GENFIT recorded a revenue of €65.4 million in 2025, boosted by royalties from Iqirvo (€21.8 million) and two milestone payments (€43.6 million) linked…
GENFIT announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD) to G1090N (nitazoxanide), its experimental candi…
Genfit has received orphan drug designation from the FDA for NTZ in the treatment of acute hepatic failure on cirrhosis (ACLF). This designation, anno…
GENFIT saw an increase of 3.53% this Thursday morning, reaching 8.94 euros, bringing its quarterly performance to over 84%. The stock of the biopharma…
